The evolution of the exchange-traded fund (ETF) brought innovative products to the fixed income marketplace. These don't just cater to buy-and-hold investors fixated on the long-term investment horizon. Ultra-short term bond funds appeal to investors looking to use the ETF wrapper to fulfill short-term cash obligations. It's what Morningstar's head of client solutions Ben Johnson referred to as "money market substitutes†in a recent episode of ETF Prime. In the same episode, Johnson picked the Vanguard 0-3 M ...

Key Points Centrus Energy occupies a critical place as the U.S. seeks to rebuild its nuclear supply chain. The company is working with the Department of Energy to produce specialized fuel for reactors. The recent stock sell-off likely reflects investor caution at the nuclear industry's lofty valuations. 10 stocks we like better than Centrus Energy › Centrus Energy (NYSE: LEU) started 2025 with a share price of about $74. In mid-October, the stock hit a 52-week high of roughly $464 a share, repres ...

Zacks Investment Research has recently initiated coverage of Cumberland Pharmaceuticals Inc. (CPIX) with an “Outperform” recommendation, citing the company’s differentiated specialty pharmaceutical model, durable revenue opportunities and multiple long-term growth drivers.Cumberland Pharmaceuticals is a Nashville-based specialty pharma company focused on acquiring, developing and commercializing branded prescription products in hospital acute care, gastroenterology and oncology markets. The company’s strate ...

Key Takeaways Nasdaq is prioritizing Market Technology and Information Services to drive organic revenue growth. Nasdaq expects 2025 revenue growth across Capital Access Platforms and Financial Technology segments. Nasdaq's acquisitions expanded its tech offerings, Canadian market access, and market surveillance. Shares of Nasdaq, Inc. (NDAQ) closed at $94.71 on Thursday, near its 52-week high of $97.63. This proximity underscores investor confidence. It has the ingredients for further price appreciation. T ...

While "the trend is your friend" when it comes to short-term investing or trading, timing entries into the trend is a key determinant of success. And increasing the odds of success by making sure the sustainability of a trend isn't easy.Often, the direction of a stock's price movement reverses quickly after taking a position in it, making investors incur a short-term capital loss. So, it's important to ensure that there are enough factors -- such as sound fundamentals, positive earnings estimate revisions, ...

Momentum investing is essentially the opposite of the tried-and-tested Wall Street adage -- "buy low and sell high." Investors following this investing style typically avoid betting on cheap stocks and waiting long for them to recover. They believe instead that one could make far more money in lesser time by "buying high and selling higher."Everyone likes betting on fast-moving trending stocks, but it isn't easy to determine the right entry point. These stocks often lose momentum when their future growth po ...

When it comes to short-term investing or trading, they say "the trend is your friend." And there's no denying that this is the most profitable strategy. But making sure of the sustainability of a trend to profit from it is easier said than done.The trend often reverses before exiting the trade, leading to a short-term capital loss for investors. So, for a profitable trade, one should confirm factors such as sound fundamentals, positive earnings estimate revisions, etc. that could keep the momentum in the st ...

Momentum investors typically don't time the market or "buy low and sell high." In other words, they avoid betting on cheap stocks and waiting long for them to recover. Instead, they believe that "buying high and selling higher" is the way to make far more money in lesser time.Who doesn't like betting on fast-moving trending stocks? But determining the right entry point isn't easy. Often, these stocks lose momentum once their valuation moves ahead of their future growth potential. In such a situation, invest ...

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Avantor, Inc. due to allegations of misleading statements regarding the company's competitive positioning and financial performance during a specified period [1][3]. Group 1: Allegations and Misleading Statements - The complaint alleges that Avantor and its executives violated federal securities laws by making false and misleading statements about the company's competitive position and failing to disclose the negative impacts of increased competition [3]. - During an earnings call on July 26, 2024, Avantor's then-CEO Michael Stubblefield assured investors of the company's strong competitive position, despite evidence suggesting otherwise [4]. Group 2: Financial Performance and Stock Impact - Investors became aware of the adverse effects of competition on Avantor's business on April 25, 2025, when the company reported disappointing Q1 2025 results, leading to a stock price decline of over 16.5% [5]. - On August 1, 2025, Avantor reported further disappointing Q2 2025 results, including a projected organic revenue growth of -2% to 0%, resulting in a stock price drop of more than 15% [6]. - The company reported weak Q3 2025 results on October 29, 2025, including a net loss of $712 million attributed to competitive pressures, causing the stock price to decline by over 23% [7]. Group 3: Legal Proceedings and Class Action - The deadline for investors to seek the role of lead plaintiff in the federal securities class action against Avantor is December 29, 2025 [1]. - Any member of the putative class can move the court to serve as lead plaintiff or remain an absent class member without affecting their ability to share in any recovery [8].

UnitedHealth Group (NYSE: UNH) has endured a brutal 2025, with shares down approximately 35% year-to- date. This marks the company's worst annual performance since 2008, when it lost more than 54% during the financial crisis. The stock reached a 52-week low around $235 in August before rebounding roughly 46% to its current levels near $328. Despite this sharp decline — or precisely because of it — the depressed valuation has created an attractive entry point for investors. Trading at a forward P/E ratio 18 ...